Journal article icon

Journal article

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

Abstract:

BACKGROUND: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-analysis was disputed by the manufacturer. OBJECTIVES: To compare the efficacy of AChEI monotherapy with combination memantine and AChEI therapy in patients with moderate-to-severe AD and to examine the i...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
Stroke and Geratology
Role:
Author
Publisher:
BMJ Publishing Group
Journal:
BMJ Open More from this journal
Publication date:
2012-01-01
Acceptance date:
2012-03-30
DOI:
EISSN:
2044-6055
ISSN:
2044-6055
Language:
English
Keywords:
UUID:
uuid:6cf40af2-9543-4127-a9ad-69ca42a929b9
Local pid:
pubs:339870
Source identifiers:
339870
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP